Antibody therapeutics - Acceleron/Adimab
Latest Information Update: 17 Oct 2014
At a glance
- Originator Acceleron Pharma; Adimab
- Class Antibodies
- Mechanism of Action TGF-beta superfamily protein-modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 12 Aug 2014 Early research in Undefined indication in USA (unspecified route)